Skip to main content
. 2021 Aug 7;9(2):347–364. doi: 10.1007/s40487-021-00167-z

Table 3.

Objective response rate in patients with ovarian and primary peritoneal cancer to niraparib treatment by BRCA mutation and platinum status

Objective response rate (n/total, %)
BRCA mutated BRCA wild-type
Platinum-sensitive 5/10 (50%) 1/3 (33%)
Platinum-resistant 3/9 (33%) 1/19 (5%)